<DOC>
	<DOCNO>NCT00030368</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine bortezomib paclitaxel treat patient advanced metastatic solid tumor . Bortezomib may stop growth cancer cell block enzymes necessary growth . Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Combining bortezomib paclitaxel may kill tumor cell .</brief_summary>
	<brief_title>Bortezomib Paclitaxel Treating Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose bortezomib give combination paclitaxel patient locally advance metastatic solid tumor . OUTLINE : This multicenter , dose-escalation study bortezomib . Patients receive bortezomib IV day 2 9 paclitaxel IV 1 hour day 1 8 . For first course , patient receive paclitaxel day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity great 80 % 20S proteasome inhibition . Once MTD determine , additional 6-9 patient accrue treated dose . Patients follow 21 day . PROJECTED ACCRUAL : A total 45 patient accrue study .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced metastatic solid tumor curative treatment No known brain metastasis Performance status ECOG 02 Performance status Karnofsky 60100 % WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST/ALT great 2.5 time upper limit normal ( ULN ) Creatinine great ULN Left ventricular function least low limit normal receive prior doxorubicin No grade II IV tilttable test No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No thrombotic event within past 6 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction compound similar chemical biological composition study drug No concurrent uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study compliance At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Prior paclitaxel allow At least 2 week since prior hormonal therapy No concurrent steroid hormonal therapy except steroid prevent hypersensitivity reaction paclitaxel hormonal therapy nondiseaserelated condition ( e.g. , insulin diabetes ) At least 4 week since prior radiotherapy At least 4 week since prior surgery Recovered prior therapy No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticoagulation therapy Concurrent pamidronate zoledronate allow treatment hypercalcemia palliation skeletal metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>